Overview

Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin

Status:
Completed
Trial end date:
2019-11-16
Target enrollment:
Participant gender:
Summary
To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.
Phase:
Phase 3
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Treatments:
Dapagliflozin